InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,565.69
(
-0.03%
)
US TECH 100
19,892.00
(
0.23%
)
Dow Jones
39,303.17
(
-0.18%
)
Brent Oil
85.51
(
-1.16%
)
Bitcoin
56,032.35
(
0.34%
)
Post# of 252509
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119984
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 148507

Tuesday, 09/11/2012 12:26:05 PM

Tuesday, September 11, 2012 12:26:05 PM

Post# of 252509
Sally Church’s take on Bavituxiamb second-line NSCLC data:

http://pharmastrategyblog.com/2012/09/update-on-bavituximab-in-non-squamous-lung-cancer.html

The above echoes many of the points already made by various posters on this board. Although Sally does not comment on accelerated approval explicitly, it’s clear from the write-up that she agrees with my view in #msg-79408126 that AA is out of the question.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up